Vitamin E and adiponectin: Proposed mechanism for vitamin E-induced improvement in insulin sensitivity

Nutrition Reviews

Volumn 69, Issue 3, 2011, Pages 155-161

  Gray, Brianna ^a   Swick, Jennifer ^a   Ronnenberg, Alayne G ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Adiponectin; Insulin sensitivity; PPAR gamma; Vitamin E

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ALPHA TOCOPHEROL; GAMMA TOCOPHEROL; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE; HUMAN; INSULIN SENSITIVITY; LIPOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROADIPOCYTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; UPREGULATION;

ADIPONECTIN; HUMANS; INSULIN; PPAR GAMMA; UP-REGULATION; VITAMIN E;

EID: 79951933572     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2011.00377.x     Document Type: Article

References (47)

1. Azzi A, Gysin R, Kempna P, etal. Regulation of gene expression by alpha-tocopherol. Biol Chem. 2004;385:585-591.
2. Paolisso G, D'Amore A, Giugliano D, Ceriello A, Varricchio M, D'Onofrio F. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. Am J Clin Nutr. 1993;57:650-656.
3. Paolisso G, Di Maro G, Galzerano D, etal. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr. 1994;59:1291-1296.
4. Salonen JT, Nyyssonen K, Tuomainen TP, etal. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. BMJ. 1995;311:1124-1127.
5. Costacou T, Ma B, King IB, Mayer-Davis EJ. Plasma and dietary vitamin E in relation to insulin secretion and sensitivity. Diabetes Obes Metab. 2008;10:223-228.
6. Mayer-Davis EJ, Costacou T, King I, Zaccaro DJ, Bell RA. Plasma and dietary vitamin E in relation to incidence of type 2 diabetes: the Insulin Resistance and Atherosclerosis Study (IRAS). Diabetes Care. 2002;25:2172-2177.
7. Sanchez-Lugo L, Mayer-Davis EJ, Howard G, etal. Insulin sensitivity and intake of vitamins E and C in African American, Hispanic, and non-Hispanic white men and women: the Insulin Resistance and Atherosclerosis Study (IRAS). Am J Clin Nutr. 1997;66:1224-1231.
8. Liu S, Lee IM, Song Y, etal. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes. 2006;55:2856-2862.
9. Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthalmic Physiol Opt. 2008;28:503-523.
10. Cabalero B. Vitamin E improves the action of insulin. Nutr Rev. 1993;51:339-340.
11. Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. Unique ability of troglitazone to upregulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J Pharmacol Exp Ther. 2002;300:72-77.
12. Vinayaga Moorthi R, Bobby Z, Selvaraj N, Sridhar MG. Vitamin E protects the insulin sensitivity and redox balance in rat L6 muscle cells exposed to oxidative stress. Clin Chim Acta. 2006;367:132-136.
13. Paz K, Hemi R, LeRoith D, etal. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem. 1997;272:29911-29918.
14. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622.
15. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7:1040-1052.
16. Campbell SE, Stone WL, Whaley SG, Qui M, Krishnan K. Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines. BMC Cancer. 2003;3:25.
17. Hsieh CC, Huang CJ, Lin BF. Low and high levels of alpha-tocopherol exert opposite effects on IL-2 possibly through the modulation of PPAR-gamma, IkappaBalpha, and apoptotic pathway in activated splenocytes. Nutrition. 2006;22:433-440.
18. De Pascale MC, Bassi AM, Patrone V, Villacorta L, Azzi A, Zingg JM. Increased expression of transglutaminase-1 and PPARgamma after vitamin E treatment in human keratinocytes. Arch Biochem Biophys. 2006;447:97-106.
19. Landrier JF, Gouranton E, El Yazidi C, etal. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology. 2009;150:5318-5325.
20. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286-289.
21. Arita Y, Kihara S, Ouchi N, etal. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
22. Kumada M, Kihara S, Sumitsuji S, etal. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-89.
23. Lindsay RS, Funahashi T, Hanson RL, etal. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-58.
24. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab. 2004;89:87-90.
25. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentrationin patients with essential hypertension. Am J Hypertens. 2003;16:72-75.
26. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
27. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463-478.
28. Iwaki M, Matsuda M, Maeda N, etal. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655-1663.
29. Combs TP, Wagner JA, Berger J, etal. Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR-gamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998-1007.
30. Kubota N, Terauchi Y, Kubota T, etal. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006;281:8748-8755.
31. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxydelta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
32. Hirata Y, Hayashi H, Ito S, etal. Occurrence of 9-deoxy-delta 9, delta 12-13, 14-dihydroprostaglandin D2 in human urine. J Biol Chem. 1988;263:16619-16625.
33. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731-37734.
34. Powell WS. 15-deoxy-Delta(12, 14-)PGJ(2): endogenous PPAR gamma ligand or minor eicosanoid degradation product? J Clin Invest. 2003;112:828-830.
35. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-Delta(12, 14)-PGJ(2) and the litigation of PPAR gamma. J Clin Invest. 2003;112:945-955.
36. Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol. 2005;114:100-109.
37. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
38. Chandra V, Jasti J, Kaur P, Betzel C, Srinivasan A, Singh TP. First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. J Mol Biol. 2002;320:215-222.
39. O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res. 2004;551:245-254.
40. Traber MG, Packer L. Vitamin E: beyond antioxidant function. Am J Clin Nutr. 1995;62(Suppl):S1501-S1509.
41. Yamauchi T, Kamon J, Ito Y, etal. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-769.
42. Yamauchi T, Kamon J, Minokoshi Y, etal. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-1295.
43. Yamauchi T, Kamon J, Waki H, etal. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946.
44. Iwabu M, Yamauchi T, Okada-Iwabu M, etal. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464:1313-1319.
45. Sun X, Zemel MB. Calcium and 1, 25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity (Silver Spring). 2007;15:340-348.
46. Shen XH, Tang QY, Huang J, Cai W. Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Exp Biol Med (Maywood). 2010;235:47-51.
47. Ristow M, Zarse K, Oberbach A, etal. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009;106:8665-8670.